Study of ARO-APOC3 in Adults With Dyslipidemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 418 participants.

Also called NCT05413135

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 418 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05413135
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Canada, Hungary, Netherlands, New Zealand, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05413135. Allocation not applicable; no masking; primary purpose treatment. Start 2022-07-07 (actual); primary completion 2025-09-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of ARO-APOC3 in Adults With Dyslipidemia
Condition
Dyslipidemias
Intervention (Drug)
ARO-APOC3
Lead sponsor
Arrowhead Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05413135
Content hash
eb642da9b7dcde3b4f5d9eee41b6b7ac908b4912e170d447d350df171aefa30f